A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Public ClinicalTrials.gov record NCT03763877. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
Study identification
- NCT ID
- NCT03763877
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2019 (Actual)
- Primary completion
- Aug 3, 2020 (Actual)
- Completion
- Aug 10, 2020 (Actual)
- Last update posted
- Oct 28, 2021
2019 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site 02 | Los Angeles | California | 90057 | — |
| Study Site 01 | Gainesville | Florida | 32610 | — |
| Study Site 11 | Ocoee | Florida | 34761 | — |
| Study Site 15 | Orlando | Florida | 32804 | — |
| Study Site 10 | Athens | Georgia | 30607 | — |
| Study Site 03 | Indianapolis | Indiana | 46260 | — |
| Study Site 07 | Marrero | Louisiana | 70072 | — |
| Study Site 05 | West Monroe | Louisiana | 71291 | — |
| Study Site 08 | Berlin | New Jersey | 08009 | — |
| Study Site 09 | Durham | North Carolina | 27710 | — |
| Study Site 13 | Rapid City | South Dakota | 57701 | — |
| Study Site 06 | Arlington | Texas | 76012 | — |
| Study Site 04 | San Antonio | Texas | 78207 | — |
| Study Site 12 | San Antonio | Texas | 78215 | — |
| Study Site 14 | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03763877, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2021 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03763877 live on ClinicalTrials.gov.